Tabuchi Hitoshi, Nishimura Kazuaki, Akada Masahiro, Ishikami Tomohiro, Shirakami Tomoki, Kamiura Naotake, Kiuchi Yoshiaki
Department of Technology and Design Thinking for Medicine, Hiroshima University, Hiroshima, Japan.
Department of Ophthalmology, Tsukazaki Hospital, Himeji, Japan.
Heliyon. 2024 Jul 5;10(14):e34167. doi: 10.1016/j.heliyon.2024.e34167. eCollection 2024 Jul 30.
To understand real-world eye drop adherence among glaucoma patients and evaluate the performance of our proposed cloud-based support for eye drop adherence (CASEA).
Prospective, observational case series.
The Department of Ophthalmology at Tsukazaki Hospital. Glaucoma patients treated at the hospital from May 2021 to September 2022, with 61 patients initially enrolled. Pharmacists guided eye drop administration before the study. Changes in bottle orientation were detected using an accelerometer attached to the container, and acceleration waveforms and date/time data were recorded. Patients visited the clinic during the 4th and 8th weeks to report their eye drop administration, and the data were uploaded to the cloud. Two AI models (B-LSTM) were created to analyze the eye drop bottle movement time-series data for patients treating one or both eyes. The models were evaluated by comparing the true administration status with the AI model judgment.
Four of the 61 study subjects dropped out. The remaining 57 patients achieved recall, precision, and accuracy values of 98.6 %, 98.6 %, and 95.9 %, respectively, for the two-eyes model and 95.8 %, 98.8 %, and 95.6 % for the one-eye model. Three low-accuracy participants (77.1 %, 71.0 %, and 81.0 %) improved to 100 %, 99.1 %, and 100 %, respectively, after undergoing an additional 8-week performance validation using an aid-type container designed to ensure that the bottle was fully inverted during instillation.
CASEA precisely monitored daily eye drop adherence and enhanced treatment efficacy by identifying patients with difficulty self-medicating. This system has the potential to improve glaucoma patient outcomes by supporting adherence.
了解青光眼患者在现实世界中的眼药水依从性,并评估我们提出的基于云的眼药水依从性支持系统(CASEA)的性能。
前瞻性观察性病例系列。
冢崎医院眼科。2021年5月至2022年9月在该医院接受治疗的青光眼患者,最初纳入61例患者。在研究前,药剂师指导眼药水给药。使用附着在容器上的加速度计检测瓶子方向的变化,并记录加速度波形和日期/时间数据。患者在第4周和第8周到诊所报告眼药水给药情况,并将数据上传到云端。创建了两个人工智能模型(B-LSTM)来分析治疗一只或两只眼睛的患者的眼药水瓶移动时间序列数据。通过将实际给药状态与人工智能模型判断进行比较来评估模型。
61名研究对象中有4人退出。其余57名患者的双眼模型召回率、精确率和准确率分别达到98.6%、98.6%和95.9%,单眼模型分别为95.8%、98.8%和95.6%。三名低准确率参与者(77.1%、71.0%和81.0%)在使用旨在确保滴注时瓶子完全倒置的辅助型容器进行额外8周的性能验证后,准确率分别提高到100%、99.1%和100%。
CASEA通过识别自我给药困难的患者,精确监测每日眼药水依从性并提高治疗效果。该系统有可能通过支持依从性来改善青光眼患者的治疗结果。